144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September-1 November 2006, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 17, Issue 6, 2007, Pages 494-498

  Quinlivan, R ^a   Vissing, J ^b  

^a ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; CREATINE; DANTROLENE; GLUCAGON; GLYCOGEN PHOSPHORYLASE; PLACEBO; PYRIDOXINE; RAMIPRIL; RIBOSE; VERAPAMIL;

AEROBIC EXERCISE; ARTICLE; CLINICAL TRIAL; DRUG DOSE COMPARISON; ENZYME ACTIVITY; GENE MUTATION; GENETIC ASSOCIATION; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; KETOGENIC DIET; MUSCLE BIOPSY; MUSCLE FATIGUE; MUSCLE FUNCTION; NETHERLANDS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM;

EXERCISE; GLYCOGEN PHOSPHORYLASE, MUSCLE FORM; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; INTERNATIONAL COOPERATION; MUTATION, MISSENSE; NETHERLANDS; NUTRITION THERAPY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 34249321269     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2007.03.001     Document Type: Article

References (24)

1. Mommaerts W.F.H., Illingworth B., Pearson C.M., Guilorg R.J., and Seraydarian K. A functional disorder of muscle associated with the absence of phosphorylase. PNAS 3 (1959) 18-22
2. Schmidt R., and Mahler R. Chronic progressive myopathy with myoglobinuria: demonstration of a glycogenolytic defect in muscle. J Clin Invest 108 (1959) 2044-2058
3. Haller R.G., and Vissing J. Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease - oxidative mechanisms. Arch Neurol 59 (2002) 1395-1402
4. Andersen S.T., Dunø M., Schwartz M., and Vissing J. Do carriers of PYGM mutations have symptoms of McArdle disease?. Neurology 67 (2006) 716-718
5. Bartram C., Edwards R.H., Clague J., and Beynon R.J. McArdle's disease a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2 (1993) 1291-1293
6. Beynon R.J., Quinlivan R.C.M., and Sewry C.A. Selected disorders of carbohydrate metabolism. In: Karpati G. (Ed). Structural and molecular basis of skeletal muscle disease (2002), Wiley 182-188
7. Haller R.G. Treatment of McArdle disease. Arch Neurol 57 (2002) 923-924
8. Bruno C., Cassandrini D., Martinuzzi A., et al. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat 27 (2006) 718-727
9. Martinuzzi A., Sartori E., Fanin M., et al. Phenotype modulators in phosphorylase deficiency. Ann Neurol 53 (1993) 497-502
10. DiMauro S., and Haller R.G. Metabolic myopathies: substrate utilisation defects. In: Griggs R.C., and Schapira A.V. (Eds). Muscle diseases (1999), Butterworth, Boston 225-249
11. Engel W.K., Eyerman E.L., and Williams H.E. Late-onset type of skeletal muscle phosphorylase activity. A new familial variety with completely and partial affected subjects. N Eng J Med 268 (1963) 135-137
12. DiMauro S., and Hartlage P. Fatal infantile form of muscle phosphorylase deficiency. Neurology 28 (1978) 1124-1129
13. Cornelio F., Bresolin N., DiMauro S., et al. Congenital myopathy due to phosphorylase deficiency. Neurology 33 (1983) 1383-1385
14. Quinlivan R.M., and Beynon R.J. Pharmacological and nutritional treatment of McArdle's disease (Glycogen storage disease V). Cochrane Database Syst Rev 3 (2004) CD003458
15. Haller R.G., Dempsey W.B., Feit H., Cook J.D., and Knochel J.P. Low levels of muscle pyridoxine in McArdle's Syndrome. Am J Med 74 (1983) 217-220
16. Phoenix J., Hopkins P., Bartram C., Beynon R.J., Quinlivan R., and Edwards R.H. Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study. Neuromuscul Disord 8 (1998) 210-212
17. Vissing J., and Haller R.G. Effect of oral sucrose on exercise intolerance in patients with McArdle's disease. N Eng J Med 349 (2003) 2503-2509
18. Vandenberghe K., Goris M., Van Hecke P., Van Leemputte M., Vangerven L., and Hespel P. Long term creatine intake is beneficial to muscle performance during resistive training. J Appl Physiol 83 (1997) 2055-2063
19. Vorgerd M., Grehl T., Jager M., et al. Creatine therapy in myophosphorylase activity (McArdle's disease). A placebo controlled crossover trial. Arch Neurol 57 (2000) 956-963
20. Vorgerd M., Zange J., Kley R., et al. Effect of high dose creatine therapy on symptoms of exercise intolerance in McArdle's disease: double-blind placebo controlled cross-over study. Arch Neurol 59 (2002) 97-101
21. Schroers A., Kley R., Stachon A., et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 66 (2006) 285-286
22. Busch V., Gempel K., Hack A., et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol 58 (2005) 341
23. Haller R.G., Wyrick P., Taivassalo P., and Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 59 (2006) 922-928
24. Ollivier K., Hogrel J.-Y., Gomez-Merino D., et al. Exercise tolerance and daily life in McArdle's disease. Muscle Nerve 31 (2005) 637-641